Synlogic has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic Biotic™ leads for the treatment of inflammatory bowel disease (IBD), including Crohn’s Disease and colitis, using the company’s proprietary discovery and development technology platform. Based on the terms of the agreement, Synlogic will receive an undisclosed milestone payment and the companies will move into the second phase of the collaboration. Synlogic is pioneering the development of a novel class of living medicines – Synthetic Biotic medicines, which perform critical functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease.
“The delivery of these investigational Synthetic Biotic medicines, as part of the first phase of our collaboration with AbbVie, demonstrates the continued potential of our discovery and development platform against a wide range of diseases,” said Jose Carlos Gutierrez-Ramos, Ph.D., president and chief executive officer of Synlogic. “We believe our living medicines have the potential to be transformational for patients, and our commitment to advance the platform’s power includes pursuing innovative partnerships such as the one we’ve forged with AbbVie.”
Under the terms of the ongoing research and development collaboration, AbbVie and Synlogic will continue to evaluate the investigational Synthetic Biotic leads as potential candidates for the treatment of IBD and advance them through preclinical development, with AbbVie having a right to subsequent clinical development and worldwide marketing of resulting products. Further detail on the terms of the deal were not disclosed.
Filed Under: Drug Discovery